Number | Sex | Age (years) | Primary tumor | Evaluable metastasis | Histology | Bevacizumab maintenance therapy | Best response | Site of progression | PFS (weeks) | OS (weeks) |
---|---|---|---|---|---|---|---|---|---|---|
1 | F | 56 | RLL | - | AC | Yes | PR | LLL | 56 | 79 |
2 | M | 51 | RUL | Peritoneum | AC | Yes | PR | PC | 13 | 17 |
3 | M | 59 | RLL | Bone | AC | Yes | PR | RULa | 27 | 48 |
4 | M | 61 | RLL | Bone | LCC | Yes | CR | RA | 35 | 63 |
5 | F | 54 | RLL | Bone | AC | Yes | PR | Brain | 54 | 74 |
6 | F | 69 | RH | Pericardium | AC | Yes | PR | MC | 34 | 60 |
7 | M | 51 | LH | Bone | AC | No | PD | Livera | 3 | 3 |